Total Voting Rights
Solvonis Therapeutics plc announced that its issued share capital as of October 31, 2025, comprises 6,806,403,493 ordinary shares, each with one voting right. The company holds no ordinary shares in treasury, resulting in a total of 6,806,403,493 ordinary shares and voting rights. This includes a correction to a previously announced share issue on the same date, with the accurate figure for shares issued and admitted being 23,636,362, revised down from the originally stated 26,636,362 shares. This figure is relevant for shareholders determining their notification requirements regarding their interest in the company's share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, confirms that the Company's issued share capital as at the date of this announcement comprises 6,806,403,493 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 6,806,403,493.
This includes an amendment to the issue of shares announced on 31 October 2025 where the correct figure to be issued and admitted is 23,636,362. The original figure announced was 26,636,362.
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.